about
Rapid internalization of the oncogenic K+ channel K(V)10.1Substrate mediated enzyme prodrug therapyHuman serum albumin and p53-activating peptide fusion protein is able to promote apoptosis and deliver fatty acid-modified moleculesComparative Phytochemical Analysis of Essential Oils from Different Biological Parts of Artemisia herba alba and Their Cytotoxic Effect on Cancer CellsSelective Cytotoxicity of 1,3,4-Thiadiazolium Mesoionic Derivatives on Hepatocarcinoma Cells (HepG2)Combinatorial peptide libraries: mining for cell-binding peptides.Recent trends in targeted anticancer prodrug and conjugate design.Investigation of self-immolative linkers in the design of hydrogen peroxide activated metalloprotein inhibitors.Prodrug strategy to achieve lyophilizable, high drug loading micelle formulations through diester derivatives of β-Lapachone.Genome-free viral capsids as multivalent carriers for taxol delivery.Prodrug applications for targeted cancer therapy.Readily accessible fluorescent probes for sensitive biological imaging of hydrogen peroxidePeptide Targeting of Fluorescein-Based Sensors to Discrete Intracellular Locales.Nanomedical engineering: shaping future nanomedicines.Synthesis and biological evaluation of neopeltolide and analogsRibonuclease-Activated Cancer Prodrug.Incorporation and controlled release of silyl ether prodrugs from PRINT nanoparticles.Enhanced Cellular Uptake and Pharmacokinetic Characteristics of Doxorubicin-Valine Amide Prodrug.Tuning cobalt(III) Schiff base complexes as activated protein inhibitors.MILD AND SELECTIVE O-GLYCOSYLATIONS OF PRIMARY ALCOHOLS WITH THE THIOGLUCOSAMINIDE DERIVATIVE PROMOTED BY N-IODOSUCCINIMIDE AND HBF(4)-ADOSROBED ON SILICA GEL.Efficient synthesis of diverse heterobifunctionalized clickable oligo(ethylene glycol) linkers: potential applications in bioconjugation and targeted drug delivery.Cathepsin B-cleavable doxorubicin prodrugs for targeted cancer therapy (Review)Near-infrared quantum dots as optical probes for tumor imaging.Emerging trends in metalloprotein inhibition.Peptide-based Targeting of Fluorescent Zinc Sensors to the Plasma Membrane of Live CellsField Guide to Challenges and Opportunities in Antibody-Drug Conjugates for Chemists.Poly(ethylene glycol)-Lipid-Conjugated Antibodies Enhance Dendritic Cell Phagocytosis of Apoptotic Cancer Cells.Silica-based mesoporous nanoparticles for controlled drug delivery.Radiation- and photo-induced activation of 5-fluorouracil prodrugs as a strategy for the selective treatment of solid tumors.Tuning the metabolism of the anticancer drug cisplatin with chemoprotective agents to improve its safety and efficacy.A Novel Tumor-Activated Prodrug Strategy Targeting Ferrous Iron Is Effective in Multiple Preclinical Cancer ModelsDesign, Synthesis, and Biological Evaluation of Potential Prodrugs Related to the Experimental Anticancer Agent Indotecan (LMP400).Modern lipid-, carbohydrate-, and peptide-based delivery systems for peptide, vaccine, and gene products.Liposomal cancer therapy: exploiting tumor characteristics.Imaging PEG-like nanoprobes in tumor, transient ischemia, and inflammatory disease modelsProdrug and conjugate drug delivery strategies for improving HIV/AIDS therapy.Targeting and delivery of platinum-based anticancer drugs.Acid-degradable polymers for drug delivery: a decade of innovation.Clinical developments of chemotherapeutic nanomedicines: polymers and liposomes for delivery of camptothecins and platinum (II) drugs.Drug delivery and release systems for targeted tumor therapy.
P2860
Q28477472-62DFD70A-F478-4A32-ADB2-DBFB7E1DBD4CQ28485159-5BC6A8DC-FADD-4439-9C36-2FB868DCEDE4Q28535347-BA313C8B-7E0E-47A6-A691-C2EDBE3D5589Q28546711-D7CCB48F-30CA-4208-B77C-B3D1C8BCF500Q28548419-F4FC3295-D738-414A-97F9-94A96BF50921Q31144876-3A0BEF05-E734-418A-8B6A-5C40B7F516C3Q33573762-98FCD4FE-571A-4F42-9C0B-075DCA8AFB52Q33934129-5B9AA01F-1925-42C1-A623-48ACDE85FE53Q34047248-9BA800B9-6262-43C8-BE16-445D21A95BC4Q34057731-BB3615DC-C92D-4994-9AE1-40EF73D583FFQ34099780-2D9E93BA-FCBA-4F06-9282-B820268220CCQ34597734-0B268414-916D-4FC1-92B0-DFC405196BE1Q34688362-68DE69D0-235F-4006-8343-997C951CD6F0Q35019550-4AA6A602-C12E-4636-8A70-D549185D4771Q35841039-CB1DB2EA-92BF-44E3-A164-87FD81B50D56Q35964892-00B5B489-758B-4419-B630-030AE4111C6BQ35995074-BCF475C8-6BF1-4E58-B900-432B6C0C21BFQ36144978-84899309-433E-4E82-81BE-1CCA2BBB6C6CQ36263648-29184E3A-5B10-439D-9F83-0B0B6E06F933Q36457826-5D7E2B2D-1682-4C37-AE93-B878CE848D66Q36581316-461B921D-570D-482D-A62E-6B928446B372Q36643541-C35F736F-D6E2-40F2-A1B5-36F1C559241DQ36777322-156D6B7B-01C0-48C1-ACEA-698DBEBF06C0Q36956841-DE2FC7A2-3100-47EE-9A5C-8BEA98FD576EQ37016458-295832F7-5287-4851-AD51-A6DC7D7AF266Q37066113-994C5550-284C-42CE-ACD7-20BB9912EBF8Q37148735-EB9E224B-344D-4202-B248-5193DAB2E194Q37151406-0374515F-6CE0-4815-9397-D407DCB0C1EDQ37284613-618F46AD-143A-4122-BC46-DFA912CDD0DFQ37441359-74F4D4C3-B956-486A-840A-53F71ED34DF6Q37532072-35B1BF90-FB73-4E3E-B578-748AC87AEF3CQ37652515-B8759A24-1557-466B-8BE5-A6F70F56B490Q37661001-5D042575-379F-4B74-9A49-FBF5198775FAQ37679954-228F1D57-F36B-4E21-AB21-F221B3341BB0Q37735698-6931B708-8828-473E-84EE-C4D147F8E0A0Q37780687-12157D81-B696-4E09-AD24-0D866BB18792Q38050063-2D680965-3259-4652-8467-37E0C0DAC385Q38074172-02750AC7-A9B0-486B-86BC-0EAD2CAC7261Q38075544-526D1EC5-E74E-4E29-881B-018715C9C248Q38363691-37D36334-2258-4E37-A42A-412E71E931D7
P2860
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Prodrug strategies in anticancer chemotherapy.
@en
type
label
Prodrug strategies in anticancer chemotherapy.
@en
prefLabel
Prodrug strategies in anticancer chemotherapy.
@en
P2093
P2860
P356
P1433
P1476
Prodrug strategies in anticancer chemotherapy.
@en
P2093
André Warnecke
Claudia Ryppa
Felix Kratz
Ivonne A Müller
P2860
P356
10.1002/CMDC.200700159
P577
2008-01-01T00:00:00Z